TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

More than 60 billion euros (£52 billion) has been wiped off the stock market value of Ozempic and Wegovy weight loss drug firm Novo Nordisk after it warned over sales and profits ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, ...

It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to ...

Novo Nordisk shares dropped as much as 17% Tuesday after the obesity drugmaker cut its full-year sales and profit outlook for ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

The Fed kept rates steady, as most economists had expected, but struck a more hawkish tone, causing a mid-afternoon stock sell-off.

Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...